Spotlight

UCL cancer immunotherapy company, Autolus, launches with £30m investment

A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.

Find out more



follow us on twitter


Henry Rummins

Media Relations Manager (Enterprise)

Henry Rummins

T: 020 7679 9063
E: h.rummins@ucl.ac.uk

Henry is responsible for media relations for enterprise activity across UCL, including student and staff entrepreneurship, corporate partnerships, business support, commercialisation of research and spinouts. He joined the team at the beginning of 2012, having previously worked as a press officer at Friends of the Earth and the Royal Geographical Society (with IBG). Henry has a BA (Hons) in Geography from the University of Oxford.